

## 2<sup>nd</sup> CRIG Industrial Partnering Event

25<sup>th</sup> October 2019 - Auditorium 4, Sint-Denijslaan 485, Ghent (Belgium)

### Preliminary program:

- 8.00-9.00      **Breakfast sessions** – Discussion tables on developments and innovation in
1. Immuno-oncology (moderators: prof. Karim Vermaelen, U(Z)Gent-CRIG & dr. Janine Arts, Janssen Pharmaceutica)
  2. Clinical trials (moderator: prof. Sylvie Rottey, U(Z)Gent-CRIG)
  3. AI and precision medicine (moderators: dr. Ingrid Maes, Inovigate, & ir. Nicolas Deruytter, ML6)
- 9:00-9:10      **Welcome**  
**Prof. Jo Vandesompele, UGent, CRIG Chairman**
- 9.10-10:00    **Plenary talk ‘Exploiting NK receptors for CAR T cell therapy of cancer’**  
**Dr. David Gilham, Celyad**
- 10:00-10:50    **Parallel sessions 1**
- Session 1A “Innovations in cancer therapy: immuno-oncology” (moderated by dr. Hetty Helsmoortel – UGent, CRIG)
- ‘CAR-T trials at UZ Gent: being a privileged partner of the industry in a novel field’  
Prof. Tessa Kerre (U(Z)Gent, CRIG)
  - ‘Challenges and hurdles in CAR-T treatment of children’  
Prof. Barbara De Moerloose (U(Z)Gent, CRIG)
  - ‘GMP facility: on site production of immunotherapeutics at UZ Gent’  
Prof. Bart Vandekerckhove (U(Z)Gent, CRIG)
  - ‘The CliniMACS Prodigy as platform for centralized CAR-T cell production’  
Jordy Blaauwendraad (Miltenyi Biotec)
  - ‘Immune Oncology Therapies at Janssen: from Drug Development to Clinical Application’  
Dr. Janine Arts (Janssen Pharmaceutica)
  - ‘Quality by Design to accelerate T-cell based process development’  
Dr. Davide Pacitti (MaSTherCell)
- Session 1B “Innovations in cancer therapy: RNA based therapies, antibody/peptide therapies and cancer vaccines” (moderated by dr. Dominic De Groote - UGent, CRIG)
- ‘NESPR and pipeline/screening platform for novel lncRNA abled therapies’  
Prof. Pieter Mestdagh (UGent, CRIG)
  - ‘Repurposing cationic amphiphiles for improved cellular delivery of RNA therapeutics’  
Prof. Koen Raemdonck (UGent, CRIG)
  - ‘Applications of vaccines adjuvant in immuno-oncology’  
Dr. Jean-François Toussaint (GlaxoSmithKline)
  - ‘mRNA Galsomes: making mRNA vaccines more effective and controlled’  
Dr. Ine Lentacker (UGent, CRIG)
  - ‘An mRNA synthetic biology approach to immuno-oncology’  
Dr. Tasuku Kitada (Strand Therapeutics)

10:50-11:10 **Coffee break & sponsor booths**

11:10-12:00 **Parallel sessions 2:**

Session 2A “Innovations in cancer therapy: immuno-oncology” (moderated by dr. Hetty Helmsmoortel – UGent, CRIG)

- ‘Taking dendritic cells to medicine: the MIDRIX platform for vaccination in lung cancer and beyond’  
Prof. Karim Vermaelen (U(Z)Gent, CRIG)
- ‘Drug targeting to lymphoid tissue’  
Prof. Bruno De Geest (UGent, CRIG)
- ‘BiTE® antibody constructs for the treatment of cancer’  
Dr. Christoph Dahlhoff (Amgen)
- ‘Accelerated human hematopoietic stem cell differentiation towards mature Natural Killer cells with enhanced antibody-dependent cytotoxic activity’  
Laura Kiekens (UGent, CRIG)
- ‘Combination of immunotherapy and radiotherapy in clinical trials’  
Prof. Piet Ost (U(Z)Gent, CRIG)

Session 2B “Cancer modelling” (moderated by dr. An Van den Bulcke - UGent, CRIG)

- ‘Dog models of naturally occurring cancer’  
Prof. Hilde de Rooster (UGent, CRIG)
- ‘Modeling leukemia/lymphoma in mice to evaluate novel therapeutic strategies’  
Prof. Steven Goossens (UGent, CRIG)
- ‘The xenopus platform for cancer modeling’  
Prof. Kris Vleminckx (UGent, CRIG)
- ‘Zebrafish as model organism to study cancer predisposition and therapy response’  
Prof. Kathleen Claes (UGent, CRIG)
- ‘Zebrafish cancer models for selecting druggable dependencies’  
Prof. Frank Speleman (UGent, CRIG)
- ‘Patient-derived xenografts and cell lines from soft-tissue sarcoma and low-grade serous ovarian carcinoma to evaluate novel therapeutic strategies’  
Prof. Olivier De Wever (UGent, CRIG)

12:00-12:50 **Speed dating round**

12.50-13.50 **Lunch, partnering discussions & sponsor booths**

13.50-14.40 **Plenary talk ‘Digital-enabled Innovations in Cancer Care’**

**Dr. Hans Hofstraat, Philips Research**

14:40-15:30 **Parallel sessions 3**

Session 3A “Precision oncology” (moderated by dr. Hetty Helmsmoortel – UGent, CRIG)

- ‘Bacterial extracellular vesicles as a biomarker for intestinal barrier permeability and microbial dysbiosis’  
Prof. An Hendrix (UGent, CRIG)
- ‘Targeted proximity ligation assays & NGS for robust detection of structural variation in fragmented FFPE samples’  
Dr. Harma Feitsma (Cergentis)
- ‘OncoLize – Treating tumors from the Inside’

- Dr. Mike de Leeuw (OncoLize)
- ‘Studying the microbiota in colorectal cancer using germfree and gnotobiotic mouse technology’  
Prof. Lars Vereecke (VIB-UGent, CRIG)
- ‘Targeting residual leukemia cells during induction chemotherapy’  
Prof. Pieter Van Vlierberghe (UGent, CRIG)
- ‘Data-driven personalised preventive healthcare’  
Dr. Sander Vansintjan (Emma.health)

Session 3B “New players in the Belgian ecosystem and spinoff projects in oncology” (moderated by dr. Daisy Flamez - UGent, CRIG)

- ‘Cancer-T, a novel platform for informing and supporting patients through digital tools’  
Prof. Tessa Kerre (U(Z)Gent, CRIG) & Rita Cortvrindt (U(Z)Gent)
- ‘A new platform for highly controlled in vitro delivery of macromolecular compounds into living cells’  
Dr. Stephan Stremersch (UGent, CRIG)
- ‘OhmX.Bio: high throughput OMICS solutions’  
Dr. Gerben Menschaert (UGent, OhmX.Bio)
- ‘Gulliver BioMed provides customized (derivatized) nanobodies’  
Prof. Jan Gettemans (UGent, CRIG, Gulliver BioMed)
- ‘BioLizard – Scientific discovery in the hands of professionals’  
Dr. Kathryn Morrissey (BioLizard)
- ‘From Poly(2-oxazoline)s to UltraPEI for cancer treatment’  
Prof. Richard Hoogenboom (UGent, CRIG, Avroxa)

15:30-15:50      **Coffee break & sponsor booths**

15:50-16:50      **Parallel sessions 4:**

Session 4A: “Platforms and technologies in (non-invasive) diagnostics” (moderated by dr. Hetty Helsmoortel – UGent, CRIG)

- ‘Detection of single nucleotide polymorphic mutations associated with therapy resistance in human whipworm by digital PCR’  
Prof. Ward De Spiegelaere (UGent, CRIG - Stilla Technologies)
- ‘High throughput immune-profiling for cancer diagnostics’  
Christof Neuman (IPDx)
- ‘Improved and non-invasive diagnosis of adult and pediatric cancers using DNA methylation profiling’  
Prof. Katleen De Preter (UGent, CRIG)
- ‘Molecular profiling of solid tumors and hematological malignancies using targeted sequencing’  
Dr. Joni Van der Meulen (UZGent, CRIG)
- ‘Cell by Design® (CbD), a cloud-based software platform that facilitates scalable, cost effective and sustainable ATMP process development’  
Ir. Dominiek Rossillion (QBD) & ir. Evan Claes (Antleron)
- ‘Contemporary proteomics for cancer research’  
Prof. Francis Impens (VIB-UGent, CRIG)

Session 4B “AI, digital health, Big Data” (moderated by dr. Ingrid Maes - Inovigate)

- ‘Deep Learning for metastasis detection in lymph nodes, and others’  
Ir. Nicolas Deruytter (ML6)
- ‘Biocartis - Idylla™ – the art of intelligence inside a box’  
Dr. Bram De Craene (Biocartis)



CANCER RESEARCH INSTITUTE GHENT

- 'Big single-cell data science for cancer application'  
Prof. Yvan Saeys (VIB-UGent, CRIG)
- 'Artificial intelligence in the field for skin cancer diagnostics'  
Prof. Lieve Brochez (U(Z)Gent, CRIG)
- 'AI in medical imaging'  
Ir. Milan Decuyper (UGent)
- 'Health re-connected, Delivering personalised and cost-efficient outcomes'  
Dr. Ingrid Maes (Inovigate)

16.50-17:00 **Summary & closing remarks**  
**Dr. Daisy Flamez, UGent, CRIG business unit**

17.00-18.00 **Networking reception & partnering discussions**

Thanks to our sponsors!

### Gold sponsors





CANCER RESEARCH INSTITUTE GHENT

Silver sponsors



IPDx

Bronze sponsors

